Holen Sie sich die Stockscreener-App
38.79
16.13%
-7.46
Handel nachbörslich:
38.63
-0.16
-0.41%
Schlusskurs vom Vortag:
$46.25
Offen:
$46.75
24-Stunden-Volumen:
3.92M
Relative Volume:
6.94
Marktkapitalisierung:
$1.11B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.47M
KGV:
-6.9301
EPS:
-5.5973
Netto-Cashflow:
$-73.92M
1W Leistung:
-20.41%
1M Leistung:
-7.00%
6M Leistung:
+109.22%
1J Leistung:
+64.36%
1-Tages-Spanne:
$38.43
$46.75
1-Wochen-Bereich:
$38.43
$49.25
52-Wochen-Spanne:
$16.54
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Vergleichen Sie LENZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
38.79 | 1.40B | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
When is the best time to exit LENZ Therapeutics Inc.Market Movers & Verified Technical Signals - newser.com
Using portfolio simulators with LENZ Therapeutics Inc. includedWeekly Trend Report & AI Powered Market Entry Ideas - newser.com
Will a bounce in LENZ Therapeutics Inc. offer an exitPortfolio Value Summary & Accurate Trade Setup Notifications - newser.com
Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch - Investing.com India
Weiss Ratings Reiterates Sell (D-) Rating for LENZ Therapeutics (NASDAQ:LENZ) - MarketBeat
Visual analytics tools that track LENZ Therapeutics Inc. performance2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Forecasting LENZ Therapeutics Inc. price range with options dataSell Signal & High Yield Stock Recommendations - newser.com
Lenz Therapeutics sells $80 million in common stock in block trade By Investing.com - Investing.com Australia
Lenz Therapeutics sells $80 million in common stock in block trade - Investing.com India
Lenz Therapeutics Announces U.S. Availability of VIZZ Eye Drops for Presbyopia - VisionMonday.com
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 3.9%Here's Why - MarketBeat
Presbyopia Market Analysis and Forecast Report 2025-2035 Featuring AbbVie, Eyenovia, Entod Pharma, L - PharmiWeb.com
Presbyopia Market Analysis and Forecast Report 2025-2035 Featuring AbbVie, Eyenovia, Entod Pharma, Lenz Therapeutics, Orasis Pharmaceuticals, and Tenpoint TherapeuticsResearchAndMarkets.com | FinancialContent - FinancialContent
Is LENZ Therapeutics Inc. forming a bottoming base2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Smart tools for monitoring LENZ Therapeutics Inc.’s price actionMarket Growth Review & AI Driven Price Forecasts - newser.com
Is LENZ Therapeutics Inc. stock affected by interest rate hikesPortfolio Gains Report & Consistent Profit Trade Alerts - newser.com
LENZ Therapeutics’s Valuation: Examining the Impact of VIZZ’s Groundbreaking FDA Approval and US Launch - Sahm
What analysts say about LENZ Therapeutics Inc stockOptions Trading Strategies & Small Investment Portfolio Growth - earlytimes.in
Chart based analysis of LENZ Therapeutics Inc. trendsJuly 2025 Trade Ideas & Daily Technical Forecast Reports - newser.com
Using economic indicators to assess LENZ Therapeutics Inc. potential2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
TD Cowen Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
LENZ Therapeutics(LENZ.US) 10% Shareholder Sells US$10.35 Million in Common Stock - 富途牛牛
BofA Securities Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Will LENZ Therapeutics Inc. stock split attract more investorsMarket Risk Summary & Safe Swing Trade Setup Alerts - newser.com
Vizz Eyedrops Now Available to Improve Near Vision in Adults - Ophthalmology Advisor
VIZZ presbyopia eye drops launch in the US - Eyes On Eyecare
Companies Like LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Invest In Growth - Yahoo Finance
LENZ launches VIZZ eye drops for presbyopia treatment in US By Investing.com - Investing.com Nigeria
LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States - InvisionMag.com
William Blair Maintains LENZ Therapeutics(LENZ.US) With Buy Rating - 富途牛牛
LENZ Therapeutics Announces Commercial Product Availability of V - GuruFocus
LENZ Therapeutics Says VIZZ 1.44% Presbyopia Eye Drops Available in US - MarketScreener
LENZ launches VIZZ eye drops for presbyopia treatment in US - Investing.com India
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States - WV News
93% Success Rate: LENZ Therapeutics Launches Revolutionary 10-Hour Eye Drops for 128M Adults with Presbyopia - Stock Titan
Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress - MSN
What drives LENZ Therapeutics Inc stock priceVolatility Trading Techniques & Superior Capital Trading Plans - earlytimes.in
Lenz Therapeutics stock hits 52-week high at 44.03 USD By Investing.com - Investing.com Nigeria
Is LENZ Therapeutics Inc a good long term investmentVWAP Trading Strategies & Consistent Double Returns - earlytimes.in
LENZ Therapeutics (NASDAQ:LENZ) Hits New 12-Month HighHere's What Happened - MarketBeat
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lenz Therapeutics Inc-Aktie (LENZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L. | 10% Owner |
Sep 30 '25 |
Sale |
46.01 |
92,030 |
4,234,695 |
764,127 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
42.23 |
90,654 |
3,828,632 |
1,183,543 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
42.23 |
44,650 |
1,885,724 |
856,157 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 25 '25 |
Sale |
39.54 |
52,419 |
2,072,738 |
1,321,640 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
47,443 |
1,850,891 |
1,274,197 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
26,161 |
1,050,392 |
1,374,059 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 25 '25 |
Sale |
39.54 |
25,818 |
1,020,888 |
924,175 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 26 '25 |
Sale |
39.01 |
23,368 |
911,655 |
900,807 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 22 '25 |
Sale |
40.15 |
12,885 |
517,356 |
949,993 |
| Versant Venture Capital VI, L. | 10% Owner |
Aug 15 '25 |
Sale |
39.50 |
145,051 |
5,729,514 |
1,430,848 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):